Zymeworks reports Phase I data for ZW191 ADC
ZW191 demonstrated an objective response rate of 44% across all response-evaluable subjects.
Syngene Thematic ADC WP
WCLC: Daiichi’s I-DXd shows 48.2% ORR in ES-SCLC trial
MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial
CytomX to continue Phase I ADC trial despite patient death
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial
China’s NMPA approves initiation of InnoCare’s trial of B7-H3 targeted ADC
Bio-Thera Solutions doses first subject in Phase III ADC ovarian cancer trial
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer
